CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research Applications

Executive Summary: CP-673451 is a potent ATP-competitive inhibitor targeting PDGFRα (IC50 = 10 nM) and PDGFRβ (IC50 = 1 nM) with high selectivity over related kinases (Pladevall-Morera et al., 2022, DOI). In cellular assays, it inhibits PDGFR-β phosphorylation in PAE-β cells at 6.4 nM, showing over 180-fold selectivity against c-Kit (IC50 = 1.1 μM). In vivo, oral administration at 50 mg/kg reduces PDGFR-β phosphorylation by >50% for 4 h in glioblastoma xenograft models and suppresses PDGF-BB-induced angiogenesis by 70–90% in mouse sponge models (ApexBio). CP-673451 demonstrates robust tumor growth suppression and microvessel density reduction in multiple xenograft models, including ATRX-deficient gliomas (DOI). The compound’s validated scope, storage, and integration into preclinical workflows are mapped for reproducible results.

Biological Rationale

Platelet-derived growth factor receptors (PDGFRα and PDGFRβ) are receptor tyrosine kinases essential for angiogenesis, tumor proliferation, and stromal interactions in malignancies. PDGFR signaling is frequently dysregulated in high-grade gliomas and other solid tumors, often in conjunction with ATRX mutations or PDGFR amplification (Pladevall-Morera et al., 2022). Therapeutic inhibition of PDGFR is a validated strategy to disrupt tumor growth and neovascularization. CP-673451 enables selective, high-affinity targeting of PDGFRα/β, allowing researchers to dissect downstream pathways and model anti-angiogenic therapies with precision (CP-673451). This molecular specificity is particularly relevant for preclinical studies of glioblastoma, where ATRX deficiency sensitizes cells to PDGFR inhibition (DOI).

Mechanism of Action of CP-673451

CP-673451 is an ATP-competitive inhibitor that binds the kinase domain of PDGFRα and PDGFRβ with nanomolar potency (IC50: 10 nM and 1 nM, respectively) (ApexBio). This binding prevents ATP from interacting with the kinase domain, thereby blocking receptor autophosphorylation and downstream signaling cascades. The compound exhibits >100-fold selectivity versus VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR, and moderate inhibition of c-Kit (IC50 = 1.1 μM). In cell-based assays with PAE-β cells, CP-673451 achieves PDGFR-β inhibition at an IC50 of 6.4 nM, with over 180-fold selectivity against c-Kit in H526 cells (Pladevall-Morera et al., 2022). This selectivity profile ensures minimal off-target kinase inhibition, enhancing interpretability in pathway studies and disease models.

Evidence & Benchmarks

• CP-673451 inhibits recombinant PDGFRα with an IC50 of 10 nM and PDGFRβ with an IC50 of 1 nM (ApexBio, product page).
• In PAE-β cellular assays, CP-673451 achieves PDGFR-β inhibition with an IC50 of 6.4 nM (ApexBio, product documentation).
• Oral administration (50 mg/kg) in C6 glioblastoma rat xenografts reduces PDGFR-β phosphorylation >50% for 4 h (ApexBio, product page).
• CP-673451 suppresses PDGF-BB-induced angiogenesis by 70–90% in mouse sponge models (ApexBio, product page).
• Tumor growth and microvessel density are significantly reduced in Colo205, LS174T, H460, and U87MG xenograft models (ApexBio, product documentation).
• ATRX-deficient high-grade glioma cells show increased sensitivity to PDGFR inhibitors, supporting targeted use in this genetic context (Pladevall-Morera et al., 2022, DOI).

For further mechanistic analysis and translational context, see CP-673451 and the Future of Selective PDGFR Inhibition, which provides a broader survey of competitive inhibitors and clinical translation. This article extends those findings by mapping precise in vitro and in vivo benchmarks for CP-673451.

Applications, Limits & Misconceptions

CP-673451 is primarily used in cancer research to study PDGFR signaling, angiogenesis inhibition, and tumor suppression in preclinical models. It is especially valuable in models of glioblastoma and tumors with ATRX deficiency, where PDGFR signaling is a driver of malignancy (Pladevall-Morera et al., 2022). The compound’s high selectivity enables precise pathway dissection and reduces off-target effects observed with less selective RTK inhibitors. However, its activity is limited by poor water solubility and the need for DMSO or ethanol as solvents. Studies should account for its moderate c-Kit inhibition at high concentrations and short duration of in vivo target inhibition (phosphorylation reduction persists for ~4 h post-dose).

Common Pitfalls or Misconceptions

• CP-673451 does not inhibit VEGFR-1 or VEGFR-2 at nanomolar concentrations; it is not a broad-spectrum angiogenesis inhibitor (product data).
• The compound is not suitable for aqueous-based assays without DMSO or ethanol due to insolubility.
• High concentrations (>1 μM) may cause moderate c-Kit inhibition, potentially confounding results in c-Kit–expressing systems (ApexBio).
• CP-673451 is not intended for clinical or human use; its application is strictly preclinical (ApexBio).
• Duration of PDGFR-β inhibition is transient in vivo (~4 h), requiring appropriate dosing schedules for sustained effects.

For troubleshooting and robust workflow tips, see CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research, which this article updates with new in vivo benchmarks and ATRX-deficiency focus.

Workflow Integration & Parameters

For optimal use, CP-673451 should be dissolved in DMSO (≥20.9 mg/mL) or ethanol (≥2.39 mg/mL with warming and sonication). The compound is insoluble in water. Stock solutions are stable at −20°C for several months; working solutions should be freshly prepared. In vitro concentrations are typically in the 1–100 nM range for PDGFR inhibition. In vivo protocols (e.g., rat glioblastoma xenograft) use 50 mg/kg oral dosing to achieve >50% PDGFR-β phosphorylation reduction for 4 h (ApexBio). Researchers should monitor for potential c-Kit effects at higher concentrations. For deeper mechanistic rationale and translational applications, see CP-673451: Redefining Precision in Targeting PDGFR Signaling; this present article provides updated claims and benchmarks in context of ATRX-deficient glioma models.

Conclusion & Outlook

CP-673451 is a validated, highly selective ATP-competitive PDGFRα/β inhibitor for cancer research. Its defined selectivity profile, robust inhibition in preclinical models, and utility in ATRX-deficient glioma workflows make it a critical tool for dissecting PDGFR signaling and modeling anti-angiogenic therapies. Future work will refine combinatorial strategies and expand its use in genetically stratified tumor models. For specifications, protocols, and ordering, see the official CP-673451 product page (B2173).